Cargando…

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

BACKGROUND: The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Kenneth H., Hendifar, Andrew E., Alese, Olatunji B., Draper, Amber, Abdelrahim, Maen, Burns, Ethan, Khan, Gazala, Cockrum, Paul, Bhak, Rachel H., Nguyen, Catherine, DerSarkissian, Maral, Duh, Mei Sheng, Bahary, Nathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319949/ https://www.ncbi.nlm.nih.gov/pubmed/34336666 http://dx.doi.org/10.3389/fonc.2021.678070

Ejemplares similares

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

2512. Decreasing Adherence to Antiretroviral Therapy over 4 Years of Follow-up in a Commercially-Insured Population of Patients with HIV
por: Priest, Julie, et al.
Publicado: (2019)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
por: Elsayed, Marwa, et al.
Publicado: (2021)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study
por: Bobbili, Priyanka, et al.
Publicado: (2020)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer
por: Bobbili, Priyanka, et al.
Publicado: (2020)

Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence
por: Adekolujo, Orimisan Samuel, et al.
Publicado: (2023)

Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
por: Chiu, Tai-Jan, et al.
Publicado: (2021)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
por: Reddy, Tejaswini Parlapalle, et al.
Publicado: (2020)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
por: Carter, Kevin A, et al.
Publicado: (2016)

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs
por: Milano, Gérard, et al.
Publicado: (2022)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Single-treatment tumor ablation with photodynamic liposomal irinotecan sucrosulfate
por: Ghosh, Sanjana, et al.
Publicado: (2022)

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
por: DerSarkissian, Maral, et al.
Publicado: (2023)

Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden
por: Huang, Shirley P, et al.
Publicado: (2023)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
por: Apple, Jon, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
por: Woo, Wonhee, et al.
Publicado: (2019)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing
por: Bernardi, Mario, et al.
Publicado: (2023)

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_17316ohk038cr6prln83k5lu0c